Phase II Clinical Trial of the Inactivated Rotavirus Vaccine

Immunogenicity and Safety of the Inactivated Rotavirus Vaccine (Vero Cells) in Toddlers and Infants Aged From 2 to 71 Months: A Randomized, Double-blinded, Placebo-controlled Phase II Clinical Trial

This study is a randomized, double-blinded, placebo-controlled phase 2 clinical trial to evaluate the immunogenicity and safety of Inactivated Rotavirus Vaccine (IRV) in children (aged 2-71 months). Primary immunogenicity endpoints in two age groups are the anti-RV neutralizing antibody geometric mean titers (GMTs) 28 days after the final dose, anti-RV neutralizing antibody geometric mean increase (GMI), and seroconversion rates between baseline and 28 days after the final dose. The secondary safety endpoints are the number of adverse events/reactions within 30 minutes after each dose, the number of solicited adverse events/reactions within 7 days after each dose, the number of unsolicited adverse events/reactions within 28/30 days after each dose, and the number of serious adverse events (SAE) between the first dose up to 6 months after the final dose. The exploratory endpoints are the anti-RV IgG and IgA antibody GMT 28 days after the final dose, GMI and seroconversion rates of anti-RV IgG and IgA antibody between baseline and 28 days after the final dose, GMT and seropositive rates of anti-RV neutralizing antibody, IgG antibody and IgA antibody 90, 180, and 360 days after the final dose. Besides, as the exploratory endpoint, the GMT, GMI, and seroconversion rates of cross-neutralizing antibodies against G3 and G9 type of RV, gene transcription differences in peripheral blood mononuclear cells on Day 0 and 28 after the final dose will be assessed.

Study Overview

• Status: Recruiting
• Conditions: Diarrhea; Rotavirus Infections
• Intervention / Treatment: Biological: IRV on a 0- and 28-day schedule; Biological: IRV on a 0-, 28- and 56-day schedule; Biological: Placebo on Day 0, 28; Biological: Placebo on Day 0, 28, 56

Detailed Description

This is a randomized, double-blinded, placebo-controlled phase 2 clinical trial to evaluate immunogenicity and safety of IRV performed in 600 subjects (aged 2-71 months). Then, 300 toddlers (aged 7-71 months) and 300 infants (aged 2-6 months) will be eligible for parallel enrollment after assessing through medical history and physical examination. Subjects from each age group will be randomly assigned to the vaccine group or placebo group in a ratio of 3:1, that is, 225 subjects of all age groups will be injected with the vaccine while 75 subjects with the placebo.

Toddlers (aged 7-71 months) will receive an injection of the vaccine or placebo in the anterolateral midthigh or deltoid muscle of the upper arm on Day 0 and 28. Infants (aged 2-6 months) will receive an injection of the vaccine or placebo in the anterolateral midthigh or deltoid muscle of the upper arm on Day 0, 28, and 56. There would be 140 subjects in each age group chosen voluntarily for the immune persistence cohort according to the order of enrollment. The duration of toddlers (aged 7-71 months) for intervention is approximately 1 month. Thus, the duration of each subject enrolled in the immune persistence cohort will be approximately 13 months while the duration of the rest of the subjects in the study will be approximately 7 months. The duration of infants (aged 2-6 months) for intervention is approximately 2 months. Thus, the duration of each subject enrolled in the immune persistence cohort will be approximately 14 months while the duration of the rest of the subjects in the study will be approximately 8 months.

For safety assessment, the observation and evaluation of adverse events (AE) from Day 0 to Days 28/30 after each dose, and serious adverse events (SAE) between the first dose up to 6 months after the final dose will be evaluated by diary/contact cards, active reports by subjects' legal guardians, or investigators' phone calls as well as face-to-face visits. Meanwhile, subjects will be observed at the site for at least 30 minutes after each dose. For immunogenicity assessment, neutralizing antibodies against the strain from which the vaccine is based (homologous ZTR-68 strain (G1P[8]), IgG antibodies, IgA antibodies of all subjects, and neutralizing antibodies against the G3 and G9 type RV in 140 subjects of each age group will be assessed. For the exploratory endpoint, the gene transcription level of PBMC will be examined for the preliminary exploration of the possible mechanism of the Inactivated Rotavirus Vaccine (Vero Cells).

• Study Type: Interventional
• Enrollment (Estimated): 600
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Hongjun Li; Phone Number: +86 13888918945; Email: lihj6912@163.com

Study Locations

• China
  • Henan
    • Kaifeng, Henan, China
      • Recruiting
      • Tongxu Center for Disease Prevention and Control
      • Contact: Li Yun; Phone Number: +86 13598759092; Email: txxxmb@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Age Requirement: Infants and toddlers aged 2 to 71 months at the time of enrollment.
• Provision of Legal Identification: Volunteers and their legal guardians or appointed representatives must provide valid legal identification documents.
• Informed Consent: Legal guardians or appointed representatives of volunteers must have the capacity to understand the informed consent document and the research process, voluntarily participate, sign the informed consent form, and be able to comply with the requirements in the study as well as complete relevant visits on time.
• No Previous Rotavirus Vaccination: Infants and toddlers enrolled in the study should not have received any rotavirus vaccines before enrollment.

Exclusion Criteria:

1. First Dose Exclusion Criteria

   Subjects meeting any of the following exclusion criteria will be not eligible for enrollment:

   • Temperature Requirement: Axillary body temperature prior to vaccination is up to 37.3°C or more.
   • Allergic History: Subjects have a history of allergies to any component of the investigational vaccine (e.g., aluminum hydroxide), any history of vaccine allergies, suspected allergies, or any other severe adverse reactions.
   • Vaccine History: Subjects received any inactivated vaccines or subunit vaccines within 7 days (including the 7th day) prior to vaccination with the investigational vaccine, or any other live attenuated vaccines or COVID-19 vaccines within 14 days (including the 14th day) prior to vaccination.
   • Health Conditions: Subjects have known congenital abnormalities, developmental disorders, genetic defects, or severe malnutrition, among other conditions.
   • Immune-Related Diseases: Subjects have compromised primary or secondary immune function, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), juvenile rheumatoid arthritis (JRA), inflammatory bowel disease, or other autoimmune diseases.
   • Gastrointestinal Conditions: Subjects have a history of intussusception or chronic gastrointestinal diseases.
   • Neurological and Mental Health: Subjects have a history of seizures, convulsions, cerebral palsy, epilepsy, mental illness, or a family history of such conditions.
   • Acute Illness: Subjects have experienced acute illnesses (e.g., fever) within 3 days prior to vaccination with the investigational vaccine.
   • Immune Therapy: Subjects have received immune-enhancing or immune-suppressing therapy within the last 3 months (continuous oral or intravenous administration for more than 14 days) prior to vaccination.
   • Coagulation Abnormalities: Subjects have a history of coagulation disorders (e.g., coagulation factor deficiency, coagulation disorders).
   • Organ Removal History: Subjects have a history of organ removal (e.g., thyroid, pancreas, liver, spleen) or have asplenia syndrome.
   • Participation in Other Clinical Studies: Subjects are currently or have plans to participate in other clinical studies before enrollment.
   • Special Conditions for Children Aged 24 Months and Below: For such children, additional exclusion criteria include difficult birth, resuscitation after suffocation, a history of neurological damage, premature birth (delivery before the 37th week of gestation), and low birth weight (less than 2500 grams).
   • Investigator's Discretion: The final exclusion criterion is the investigator's discretion to determine whether a subject is suitable for participation in the study.

2. Contraindication of the second and third doses of vaccine

   • Severe Adverse Reactions: Subjects experienced severe adverse reactions after receiving the previous vaccine dose.
   • No Longer Meeting Inclusion Criteria or Meeting First Dose Exclusion Criteria: New conditions that disqualify them from meeting inclusion criteria or that meet the exclusion criteria for the first dose occur after receiving the previous dose, as determined by the investigator.
   • Vaccination with Other Rotavirus Vaccines During the Study: Subjects received other rotavirus vaccines during the study period.
   • Other Exclusion Reasons as Determined by the Investigator: The investigator determines other reasons for exclusion.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Tolldlers (7-71 months old, two-dose); Inactivated Rotavirus vaccine (Vero cell) in toddlers aged 7-71 months old on Day 0, 28	Biological: IRV on a 0- and 28-day schedule; Inactivated Rotavirus vaccine (Vero Cells) of 320EU/0.5ml on Day 0, 28
Experimental: Infants (2-6 months old, three-dose); Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on Day 0, 28, 56	Biological: IRV on a 0-, 28- and 56-day schedule; Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on Day 0, 28, 56
Placebo Comparator: Placebo in Tolldlers (7-71 months old, two-dose); Two doses of placebo at the vaccination schedule of Day 0, 28	Biological: Placebo on Day 0, 28; Two doses of placebo at the vaccination schedule of Day 0, 28
Placebo Comparator: Placebo in Infants (2-6 months old, three-dose); Three doses of placebo at the vaccination schedule of Day 0, 28, 56	Biological: Placebo on Day 0, 28, 56; Three doses of placebo at the vaccination schedule of Day 0, 28, 56

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Immunogenicity index-geometric mean titer (GMT) of neutralizing antibody	Neutralizing antibody assay will be performed using the neutralization and ELISA method.	Day 28 after the second vaccination
Immunogenicity index-geometric mean titer (GMT) of neutralizing antibody	Neutralizing antibody assay will be performed using the neutralization and ELISA method.	Day 28 after the third vaccination
Immunogenicity index-geometric mean increase (GMI) of neutralizing antibody	Neutralizing antibody assay will be performed using the neutralization and ELISA method.	Between baseline and day 28 after the second vaccination
Immunogenicity index-geometric mean increase (GMI) of neutralizing antibody	Neutralizing antibody assay will be performed using the neutralization and ELISA method.	Between baseline and day 28 after the third vaccination
Immunogenicity index-seroconversion rates of neutralizing antibody	Neutralizing antibody assay will be performed using the neutralization and ELISA method. Seroconversion will be defined as a change from seronegative (<1:8) to seropositive (≥1:8), or a ≥4-fold increase from baseline.	Between baseline and day 28 after the second vaccination
Immunogenicity index-seroconversion rates of neutralizing antibody	Neutralizing antibody assay will be performed using the neutralization and ELISA method. Seroconversion will be defined as a change from seronegative (<1:8) to seropositive (≥1:8), or a ≥4-fold increase from baseline.	Between baseline and day 28 after the third vaccination

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety index-incidence of adverse reactions/events	Incidence of adverse reactions/events after the first dose vaccination.	0-30 minutes after the first dose vaccination
Safety index-incidence of adverse reactions/events	Incidence of adverse reactions/events after the second dose vaccination.	0-30 minutes after the second dose vaccination
Safety index-incidence of adverse reactions/events	Incidence of adverse reactions/events after the third dose vaccination.	0-30 minutes after the third dose vaccination
Safety index-incidence of solicited adverse reactions/events	Incidence of solicited adverse reactions/events after the first dose vaccination.	Day 0 to 7 after the first dose vaccination
Safety index-incidence of solicited adverse reactions/events	Incidence of solicited adverse reactions/events after the second dose vaccination.	Day 0 to 7 after the second dose vaccination
Safety index-incidence of solicited adverse reactions/events	Incidence of solicited adverse reactions/events after the third dose vaccination.	Day 0 to 7 after the third dose vaccination
Safety index-incidence of unsolicited adverse reactions/events	Incidence of unsolicited adverse reactions/events after the first dose vaccination.	Day 0 to 28 after the first dose vaccination
Safety index-incidence of unsolicited adverse reactions/events	Incidence of unsolicited adverse reactions/events after the second dose vaccination.	Day 0 to 28/30 after the second dose vaccination
Safety index-incidence of unsolicited adverse reactions/events	Incidence of unsolicited adverse reactions/events after the third dose vaccination.	Day 0 to 30 after the third dose vaccination
Safety index-incidence of serious adverse events	Occurrence of serious adverse reactions/events after vaccination.	From the beginning of the vaccination up to 6 months after the last vaccination completed

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Immunogenicity index-geometric mean titer (GMT) of IgG antibody	IgG antibody assay will be performed using the ELISA method.	Day 28 after the second vaccination
Immunogenicity index-geometric mean titer (GMT) of IgG antibody	IgG antibody assay will be performed using the ELISA method.	Day 28 after the third vaccination
Immunogenicity index-geometric mean increase (GMI) of IgG antibody	IgG antibody assay will be performed using the ELISA method.	Between baseline and day 28 after the second vaccination
Immunogenicity index-geometric mean increase (GMI) of IgG antibody	IgG antibody assay will be performed using the ELISA method.	Between baseline and day 28 after the third vaccination
Immunogenicity index-seroconversion rates of IgG antibody	IgG antibody assay will be performed using the ELISA method. Seroconversion will be defined as a change from seronegative (≤1:16) to seropositive (>1:16), or a ≥4-fold increase from baseline.	Between baseline and day 28 after the second vaccination
Immunogenicity index-seroconversion rates of IgG antibody	IgG antibody assay will be performed using the ELISA method. Seroconversion will be defined as a change from seronegative (≤1:16) to seropositive (>1:16), or a ≥4-fold increase from baseline.	Between baseline and day 28 after the third vaccination
Immunogenicity index-geometric mean titer (GMT) of IgA antibody	IgA antibody assay will be performed using the ELISA method.	Day 28 after the second vaccination
Immunogenicity index-geometric mean titer (GMT) of IgA antibody	IgA antibody assay will be performed using the ELISA method.	Day 28 after the third vaccination
Immunogenicity index-geometric mean increase (GMI) of IgA antibody	IgA antibody assay will be performed using the ELISA method.	Between baseline and day 28 after the second vaccination
Immunogenicity index-geometric mean increase (GMI) of IgA antibody	IgA antibody assay will be performed using the ELISA method	Between baseline and day 28 after the third vaccination
Immunogenicity index-seroconversion rates of IgA antibody	IgA antibody assay will be performed using the ELISA method. Seroconversion will be defined as a change from seronegative (<1:8) to seropositive (≥1:8), or a ≥4-fold increase from baseline.	Between baseline and day 28 after the second vaccination
Immunogenicity index-seroconversion rates of IgA antibody	IgA antibody assay will be performed using the ELISA method. Seroconversion will be defined as a change from seronegative (<1:8) to seropositive (≥1:8), or a ≥4-fold increase from baseline.	Between baseline and day 28 after the third vaccination
Immunogenicity index-geometric mean titer (GMT) of IgG antibody	IgG antibody assay will be performed using the ELISA method.	Day 90,180 and 360 after the second vaccination
Immunogenicity index-geometric mean titer (GMT) of IgG antibody	IgG antibody assay will be performed using the ELISA method.	Day 90,180 and 360 after the third vaccination
Immunogenicity index-seropositive rates of IgG antibody	IgG antibody assay will be performed using the ELISA method. Seropositivity will be defined as the seropositive results (>1:16).	Day 90,180 and 360 after the second vaccination
Immunogenicity index-seropositive rates of IgG antibody	IgG antibody assay will be performed using the ELISA method. Seropositivity will be defined as the seropositive results (>1:16).	Day 90,180 and 360 after the third vaccination
Immunogenicity index-geometric mean titer (GMT) of IgA antibody	IgA antibody assay will be performed using the ELISA method.	Day 90,180 and 360 after the second vaccination
Immunogenicity index-geometric mean titer (GMT) of IgA antibody	IgA antibody assay will be performed using the ELISA method.	Day 90,180 and 360 after the third vaccination
Immunogenicity index-seropositve rates of IgA antibody	IgA antibody assay will be performed using the ELISA method. Seropositivity will be defined as the seropositive results (≥1:8).	Day 90,180 and 360 after the second vaccination
Immunogenicity index-seropositive rates of IgA antibody	IgA antibody assay will be performed using the ELISA method. Seropositivity will be defined as the seropositive results (≥1:8).	Day 90,180 and 360 after the third vaccination
Immunogenicity index-geometric mean titer (GMT) of neutralizing antibody	Neutralizing antibody assay will be performed using the neutralization and ELISA method.	Day 90,180 and 360 after the second vaccination
Immunogenicity index-geometric mean titer (GMT) of neutralizing antibody	Neutralizing antibody assay will be performed using the neutralization and ELISA method.	Day 90,180 and 360 after the third vaccination
Immunogenicity index-seropositive rates of neutralizing antibody	Neutralizing antibody assay will be performed using the neutralization and ELISA method. Seropositivity will be defined as the seropositive results (≥1:8).	Day 90,180 and 360 after the second vaccination
Immunogenicity index-seroconversion rates of neutralizing antibody	Neutralizing antibody assay will be performed using the neutralization and ELISA method. Seropositivity will be defined as the seropositive results (≥1:8).	Day 90,180 and 360 after the third vaccination
Immunogenicity index-geometric mean titer (GMT) of cross- neutralizing antibody	Neutralizing antibody assay will be performed using the neutralization and ELISA method.	Day 28 after the second vaccination
Immunogenicity index-geometric mean titer (GMT) of cross-neutralizing antibody	Neutralizing antibody assay will be performed using the neutralization and ELISA method.	Day 28 after the third vaccination
Immunogenicity index-geometric mean increase (GMI) of cross-neutralizing antibody	Neutralizing antibody assay will be performed using the neutralization and ELISA method.	Between baseline and day 28 after the second vaccination
Immunogenicity index-geometric mean increase (GMI) of cross-neutralizing antibody	Neutralizing antibody assay will be performed using the neutralization and ELISA method.	Between baseline and day 28 after the thrid vaccination
Immunogenicity index-seroconversion rates of cross-neutralizing antibody	Neutralizing antibody assay will be performed using the neutralization and ELISA method. Seroconversion will be defined as a change from seronegative (<1:8) to seropositive (≥1:8), or a ≥4-fold increase from baseline.	Between baseline and day 28 after the second vaccination
Immunogenicity index-seroconversion rates of cross-neutralizing antibody	Neutralizing antibody assay will be performed using the neutralization and ELISA method. Seroconversion will be defined as a change from seronegative (<1:8) to seropositive (≥1:8), or a ≥4-fold increase from baseline.	Between baseline and day 28 after the thrid vaccination
mRNA sequencing analysis of peripheral blood monouclear cells（PBMCs）	Differentially expressed genes of infants（2-6 months）between baseline and day 28 after the third vaccination will be measured by mRNA sequencing	Between baseline and day 28 after the third vaccination

Collaborators and Investigators

• Sponsor: Institute of Medical Biology, Chinese Academy of Medical Sciences
• Collaborators: Henan Center for Disease Control and Prevention
• Investigators: Principal Investigator: Yanxia Wang, Henan Center for Disease Control and Prevention

Study record dates

Study Major Dates

• Study Start (Actual): October 20, 2023
• Primary Completion (Estimated): February 17, 2025
• Study Completion (Estimated): June 17, 2025

Study Registration Dates

• First Submitted: October 8, 2023
• First Submitted That Met QC Criteria: October 8, 2023
• First Posted (Actual): October 12, 2023

Study Record Updates

• Last Update Posted (Estimated): January 3, 2024
• Last Update Submitted That Met QC Criteria: January 1, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: Diarrhea; Rotavirus Infections; Inactivated Rotavirus Vaccine
• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Signs and Symptoms, Digestive; Reoviridae Infections; Diarrhea; Rotavirus Infections
• Other Study ID Numbers: RV-201

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No